These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36059465)

  • 1. The antitumor effect induced by an IL-2 'no-alpha' mutein depends on changes in the CD8
    Carmenate T; Montalvo G; Lozada SL; Rodriguez Y; Ortiz Y; Díaz C; Avellanet J; Kim J; Surh CD; Graça L; León K
    Front Immunol; 2022; 13():974188. PubMed ID: 36059465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease.
    Peterson LB; Bell CJM; Howlett SK; Pekalski ML; Brady K; Hinton H; Sauter D; Todd JA; Umana P; Ast O; Waldhauer I; Freimoser-Grundschober A; Moessner E; Klein C; Hosse RJ; Wicker LS
    J Autoimmun; 2018 Dec; 95():1-14. PubMed ID: 30446251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human IL-2 mutein with higher antitumor efficacy than wild type IL-2.
    Carmenate T; Pacios A; Enamorado M; Moreno E; Garcia-Martínez K; Fuente D; León K
    J Immunol; 2013 Jun; 190(12):6230-8. PubMed ID: 23677467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
    Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interruption of the intratumor CD8
    Geels SN; Moshensky A; Sousa RS; Murat C; Bustos MA; Walker BL; Singh R; Harbour SN; Gutierrez G; Hwang M; Mempel TR; Weaver CT; Nie Q; Hoon DSB; Ganesan AK; Othy S; Marangoni F
    Cancer Cell; 2024 Jun; 42(6):1051-1066.e7. PubMed ID: 38861924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A rationally-engineered IL-2 improves the antitumor effect of anti-CD20 therapy.
    Casadesús AV; Deligne C; Diallo BK; Sosa K; Josseaume N; Mesa C; León K; Hernández T; Teillaud JL
    Oncoimmunology; 2020 Jun; 9(1):1770565. PubMed ID: 32923126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Robust IL-2-dependent antitumor immunotherapy requires targeting the high-affinity IL-2R on tumor-specific CD8
    LaPorte KM; Hernandez R; Santos Savio A; Malek TR
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37270181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-associated Tregs obstruct antitumor immunity by promoting T cell dysfunction and restricting clonal diversity in tumor-infiltrating CD8+ T cells.
    Noyes D; Bag A; Oseni S; Semidey-Hurtado J; Cen L; Sarnaik AA; Sondak VK; Adeegbe D
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35618289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained IL-2R signaling of limited duration by high-dose mIL-2/mCD25 fusion protein amplifies tumor-reactive CD8
    Hernandez R; Toomer KH; Põder J; Santos Savio A; Hsiung S; Malek TR
    Cancer Immunol Immunother; 2021 Apr; 70(4):909-921. PubMed ID: 33037893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel human IL-2 mutein with minimal systemic toxicity exerts greater antitumor efficacy than wild-type IL-2.
    Chen X; Ai X; Wu C; Wang H; Zeng G; Yang P; Liu G
    Cell Death Dis; 2018 Sep; 9(10):989. PubMed ID: 30250191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vivo Expansion of Antigen-Specific Regulatory T Cells through Staggered Fc.IL-2 Mutein Dosing and Antigen-Specific Immunotherapy.
    Pham MN; Khoryati L; Jamison BL; Hayes E; Sullivan JM; Campbell DJ; Gavin MA
    Immunohorizons; 2021 Sep; 5(9):782-791. PubMed ID: 34583939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A PD-1-targeted, receptor-masked IL-2 immunocytokine that engages IL-2Rα strengthens T cell-mediated anti-tumor therapies.
    Wu J; Bloch N; Chang AY; Bhavsar R; Wang Q; Crawford A; DiLillo DJ; Vazzana K; Mohrs K; Dudgeon D; Patel S; Ahmed H; Garg V; Amatulli M; Antao OQ; Yan Y; Wang S; Ramos W; Krueger P; Adler C; Ni M; Wei Y; Guo C; Macdonald L; Huang T; Ullman E; Hermann A; Yancopoulos GD; Murphy AJ; Davis S; Olson WC; Lin JC; Smith E; Zhang T
    Cell Rep Med; 2024 Oct; 5(10):101747. PubMed ID: 39326410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining computational and experimental biology to develop therapeutically valuable IL2 muteins.
    León K; García-Martínez K; Carmenate T; Rojas G
    Semin Oncol; 2018 Jan; 45(1-2):95-104. PubMed ID: 30318089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory T cells and myeloid-derived suppressor cells in the tumor microenvironment undergo Fas-dependent cell death during IL-2/αCD40 therapy.
    Weiss JM; Subleski JJ; Back T; Chen X; Watkins SK; Yagita H; Sayers TJ; Murphy WJ; Wiltrout RH
    J Immunol; 2014 Jun; 192(12):5821-9. PubMed ID: 24808361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MK-6, a novel not-α IL-2, elicits a potent antitumor activity by improving the effector to regulatory T cell balance.
    Kobayashi M; Kojima K; Murayama K; Amano Y; Koyama T; Ogama N; Takeshita T; Fukuhara T; Tanaka N
    Cancer Sci; 2021 Nov; 112(11):4478-4489. PubMed ID: 34545658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-infiltrating mast cells stimulate ICOS
    Lv Y; Tian W; Teng Y; Wang P; Zhao Y; Li Z; Tang S; Chen W; Xie R; Lü M; Zhuang Y
    J Adv Res; 2024 Mar; 57():149-162. PubMed ID: 37086778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent immunomodulatory and antitumor effect of anti-CD20-IL2no-alpha tri-functional immunocytokine for cancer therapy.
    Casadesús AV; Cruz BM; Díaz W; González MÁ; Gómez T; Fernández B; González A; Ledón N; Sosa K; Castro K; López A; Plasencia C; Ramírez Y; Teillaud JL; Hernández C; León K; Hernández T
    Front Immunol; 2022; 13():1021828. PubMed ID: 36569901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity.
    Xu Y; Carrascosa LC; Yeung YA; Chu ML; Yang W; Djuretic I; Pappas DC; Zeytounian J; Ge Z; de Ruiter V; Starbeck-Miller GR; Patterson J; Rigas D; Chen SH; Kraynov E; Boor PP; Noordam L; Doukas M; Tsao D; Ijzermans JN; Guo J; Grünhagen DJ; Erdmann J; Verheij J; van Royen ME; Doornebosch PG; Feldman R; Park T; Mahmoudi S; Dorywalska M; Ni I; Chin SM; Mistry T; Mosyak L; Lin L; Ching KA; Lindquist KC; Ji C; Londono LM; Kuang B; Rickert R; Kwekkeboom J; Sprengers D; Huang TH; Chaparro-Riggers J
    Cancer Immunol Res; 2021 Oct; 9(10):1141-1157. PubMed ID: 34376502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation.
    Sim GC; Liu C; Wang E; Liu H; Creasy C; Dai Z; Overwijk WW; Roszik J; Marincola F; Hwu P; Grimm E; Radvanyi L
    Cancer Immunol Res; 2016 Nov; 4(11):983-994. PubMed ID: 27697858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of IL-12 on Tregs and non-Treg T cells: roles of IFN-γ, IL-2 and IL-2R.
    Zhao J; Zhao J; Perlman S
    PLoS One; 2012; 7(9):e46241. PubMed ID: 23029447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.